Welcome to our dedicated page for Oncolytics Biotech SEC filings (Ticker: ONCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Oncolytics Biotech filings document a clinical-stage oncology company developing pelareorep and reporting material events through Form 8-K disclosures. Recent filings cover pelareorep study updates in metastatic colorectal cancer and squamous cell anal carcinoma, FDA-related development communications, translational data presented from GOBLET and AWARE-1, and incorporation of certain exhibits into a Form F-3 registration statement.
The company's regulatory record also documents capital-structure matters, including Nasdaq-listed ONCY common stock and an open-market sale agreement, as well as corporate-status changes tied to its completed continuance and domestication from Canadian jurisdictions to Nevada. These filings describe governance approvals, registered securities, financing arrangements, and oncology development disclosures for the issuer.
Oncolytics Biotech Inc. filed a Form 6-K as a foreign private issuer. The filing mainly updates how certain shareholder information is incorporated into an existing Canadian shelf-style registration statement on Form F-10. It states that Exhibit 99.1 to this Form 6-K, an information circular previously filed on July 8, 2025, is now incorporated by reference into Oncolytics Biotech Inc.’s Form F-10 registration statement (File No. 333-281009). The report is signed on behalf of the company by its Chief Financial Officer, Kirk Look.
Oncolytics Biotech Inc. filed a Form 6-K as a foreign private issuer. The filing mainly updates how certain shareholder information is incorporated into an existing Canadian shelf-style registration statement on Form F-10. It states that Exhibit 99.1 to this Form 6-K, an information circular previously filed on July 8, 2025, is now incorporated by reference into Oncolytics Biotech Inc.’s Form F-10 registration statement (File No. 333-281009). The report is signed on behalf of the company by its Chief Financial Officer, Kirk Look.